Corey Williams
Corey Williams's Latest Posts
SET Portfolio Update November 2013
November 5, 2013 Dear Sector ETF Trader Reader, As we head into the final months of the year, remember to take time away from the everyday grind of work and your investments to spend time with friends and family. After all, what is all of your hard work for if you don’t take a moment […]
BST Position Update: October 23, 2013
October 23, 2013 . . . . Prana Biotechnology (NASDAQ: PRAN) – Buy up to $4.40 Prana was just added to the portfolio last week. This exciting biotech is developing drugs for the treatment of neurological disorders. It’s leading drug candidate is PBT2, which is in phase 2 testing for Alzheimer’s (IMAGINE) and Huntington diseases […]
BST Trade Alert: October 17, 2013
October 17, 2013 Recommendation: Buy Prana Biotechnology (NASDAQ: PRAN) up to $4.40 per share. About the Company: Prana is a stock that we’ve traded before with great success. Back in October 2012, we closed out a trade in this exciting biotech for a terrific 55% gain. Now, we have an opportunity for even better returns. I’ll explain […]
SET Monthly Issue October 2013
October 2013 DON’T ‘SHUTDOWN’ – THE BULL MARKET IS GOING STRONG A lot has been made of the government shutdown and looming debt ceiling lately. The two are often tied together but they’re really completely separate issues. The government shutdown is a headwind for the economy. But it’s not the end of the world. After […]
SET Portfolio Update October 2013
October 1, 2013 Dear Sector ETF Trader Reader, We’re kicking off the month of October with more stupidity out of Washington. Our elected leaders failed to reach a deal to fund the Federal Government. Now the government is shut down. And we’re being held hostage by the stupidity of these fringe interests. And there are […]
BST Position Update: September 27, 2013
September 27, 2013 . . . . Cyclacel Pharmaceuticals (NASDAQ: CYCC) – Hold Cyclacel is our latest addition to the portfolio. This fascinating biotech is pioneering orally available, small molecule drugs that target various phases of cell cycle control. The company’s leading drug candidate is sapacitabine, which has potential to treat both blood cancers and […]
SET Monthly Issue September 2013
September 2013 FORGET ABOUT THE ‘TAPER’ AND GET ONBOARD WITH GLOBAL GROWTH US stocks weathered a rough August and are on the upswing once again… The S&P 500 reached an all-time high of 1,709 on August 2nd. Then over the rest of the month, it shed 4.5%. But since the calendar flipped to September, the […]
SET Portfolio Update September 2013
September 3, 2013 Dear Sector ETF Trader Reader, I hope you enjoyed your Labor Day weekend. Words can’t explain how excited I am for the return of football… I watched too many college games to count and ate more than my fair share of burgers and great BBQ. The holiday also marked the end of […]
BST Trade Alert: September 3, 2013
September 3, 2013 Recommendation: Buy Cyclacel Pharmaceuticals (NASDAQ: CYCC) up to $3.40 per share. About the Company: Cyclacel is a fascinating company with big upside potential. This tiny biotech is pioneering orally available, small-molecule drugs that target the various phases of cell cycle control. It’s primary disease targets are two forms of cancer, acute myeloid leukemia (AML) […]
BST Position Update: August 22, 2013
August 22, 2013 . . . . Vical (NASDAQ: VICL) – Sell Vical announced bad news last week. The company reported that its melanoma drug candidate, Allovectin, failed its phase 3 trial. And as a result, the stock dropped significantly on the news. With no upside catalysts on the horizon, Vical is likely doomed to […]
